Johnson & Johnson (JNJ) Tops Q3 EPS by 10c; Raises Outlook
Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.90, $0.10 better than the analyst estimate of $1.80. Revenue for the quarter came in at $19.7 billion versus the consensus estimate of $19.28 billion.
GUIDANCE:
Johnson & Johnson raised its FY outlook. The company sees FY2017 EPS of $7.25-$7.30, versus the consensus of $7.18. Johnson & Johnson sees FY2017 revenue of $76.1-76.5 billion, versus the consensus of $75.83 billion.
"Johnson & Johnson accelerated growth in the third quarter. This is driven by the strong performance of our Pharmaceutical business, and augmented by Actelion and other recent acquisitions across the enterprise that will continue to fuel growth," said Alex Gorsky, Chairman and Chief Executive Officer. "Our dedicated colleagues continue to focus on advancing our pipelines to bring innovative solutions to patients and consumers around the globe."
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.